Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 345

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 345
---
 any grant not yet received
is recognised in accrued income.

In 1H24 the company
recognised R&D costs of £0.2 million on the FAP project, this was made up of expenditure of £0.5 million netted against
CPRIT grant of £0.3 million.

| F-7 |

The balances as
at June 30, 2024 were as follows in relation to the FAP project:

| Schedule of relation the FAP |              |
| Prepayments                  | £1.2 million |
| Deferred revenue             | £0.1 million |

| 3. | Finance income and expense |

| Schedule of finance income                            |     |               Six months 
               ended June 
 30, 2024 unaudited £’000 |     |               Six months 
               ended June 
 30, 2023 unaudited £’000 |
|:------------------------------------------------------|:----|-------------------------:|:----|-------------------------:|
| Finance income                                        |     |                          |     |                          |
| Interest received on bank deposits                    |     |                       86 |     |                       24 |
| Other interest                                        |     |                        2 |     |                        - |
| Gain on equity settled derivative financial liability |     |                      751 |     |                      386 |
| Total finance income                                  |     |                      839 |     |                      410 |

The gain on the
equity settled derivative financial liability in 1H24 and 1H23 arose as a result of the fall in the Biodexa share price.

|                                            |     |               Six months 
               ended June 
 30, 2024 unaudited £’000 |     |               Six months 
               ended June 
 30, 2023 unaudited £’000 |
|:-------------------------------------------|:----|-------------------------:|:----|-------------------------:|
| Finance expense                            |     |                          |     |                          |
| Interest expense on lease liabilities      |     |                       11 |     |                       15 |
| Interest expense on deferred consideration |     |                       38 |     |                        - |
| Other loans                                |     |                        - |     |                        7 |
| Total finance expense                      |     |                       49 |     |                       22 |

| 4. | Taxation |

Income tax is recognised
or provided at amounts expected to be recovered or to be paid using the tax